Brief: Atossa Therapeutics Says Had Until April 3 To Regain Nasdaq Compliance
04/04/2023 19:59
April 4 (Reuters) - Atossa Therapeutics Inc ATOS.O :
* ATOSSA THERAPEUTICS - COMPANY HAD UNTIL APRIL 3, 2023 TO
REGAIN
NASDAQ COMPLIANCE OR OBTAIN AN EXTENSION OF THE DEADLINE TO
COMPLY
* ATOSSA THERAPEUTICS - APPLIED FOR AN EXTENSION AND ON
APRIL 4,
2023, CO WAS INFORMED THE DEADLINE FOR COMPLIANCE WAS EXTENDED
BY 180 DAYS
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary